Clinical Assessment of Weight Gain with Atypical Antipsychotics - Blonanserin vs Amisulpride

Background: Atypical antipsychotics appear to have the greatest potential to induce weight gain. Antipsychotic-induced weight gain is the one of main cause of non-compliance and discontinuation of treatment, often resulting in the relapse of psychosis. Objective: To compare the weight gain betw...

Full description

Bibliographic Details
Main Authors: TS DEEPAK, BN RAVEESH, BM PARASHIVAMURTHY, MS NARENDRA KUMAR, SUMANTH MALLIKARJUNA MAJGI, HN NAGESH
Format: Article
Language:English
Published: JCDR Research and Publications Private Limited 2015-06-01
Series:Journal of Clinical and Diagnostic Research
Subjects:
Online Access:https://jcdr.net/articles/PDF/6066/13007_CE[Ra1]_F(AK)_PF1(PAK)_PFA(AK)_PF2(PAG).pdf
id doaj-13c69650d332419098ffdd8811a35a59
record_format Article
spelling doaj-13c69650d332419098ffdd8811a35a592020-11-25T04:04:44ZengJCDR Research and Publications Private LimitedJournal of Clinical and Diagnostic Research2249-782X0973-709X2015-06-0196FC07FC1010.7860/JCDR/2015/13007.6066Clinical Assessment of Weight Gain with Atypical Antipsychotics - Blonanserin vs AmisulprideTS DEEPAK0BN RAVEESH1BM PARASHIVAMURTHY2MS NARENDRA KUMAR3SUMANTH MALLIKARJUNA MAJGI4HN NAGESH5Postgraduate, Department of Pharmacology, MMC&RI, Mysore, India.Professor and Head, Department of Psychiatry, MMC&RI, Mysore, India.Professor and Head, Department of Pharmacology, MMC&RI, Mysore, India.Assistant Professor, Department of Psychiatry, MMC&RI, Mysore, India.Assistant Professor, Department of Community Medicine, MMC&RI, Mysore, India.Assistant Professor, Department of Pharmacology, MMC&RI, Mysore, India.Background: Atypical antipsychotics appear to have the greatest potential to induce weight gain. Antipsychotic-induced weight gain is the one of main cause of non-compliance and discontinuation of treatment, often resulting in the relapse of psychosis. Objective: To compare the weight gain between amisulpride and blonanserin treatment, in persons with psychosis. Materials and Methods: Fifty six subjects with psychosis attending psychiatry department at KR Hospital, Mysore were randomized into two equal groups. After obtaining informed consent, subjects of group I received amisulpride tablets 200 mg BD, and group II received blonanserin tablets 4 mg BD, for eight weeks. Body weight, Body Mass Index (BMI) and Waist Hip Ratio (WHR) were measured at baseline, 4 weeks and 8 weeks. Results: The mean weight gain with amisulpride at 4 weeks was 2.73 kg (5.21%) and at 8 weeks was 4.34 kg (8.28%) from the baseline. The mean weight gain with blonanserin at 4 weeks was 1.77 kg (3.46%) and at 8 weeks was 3.46 kg (6.75%) from the baseline. The mean BMI increase at 8 weeks with amisulpride was 1.66 ± 0.56 and with blonanserin was 1.34 ± 0.77. The mean WHR increase at 8 weeks with amisulpride was 0.036 ± 0.026 and with blonanserin was 0.029 ± 0.020. There was statistically significant increase in weight, BMI and WHR associated with both blonanserin and amisulpride at 8 weeks. But there was no statistically significant difference in those parameters between blonanserin and amisulpride, at eight weeks. Conclusion: Even though there was no significant difference in the weight gain caused by blonanserin, in comparison with amisulpride, both these drugs individually caused significant weight gain at 8 weeks, which is in contrast with the earlier studies, which needs to be further evaluated.https://jcdr.net/articles/PDF/6066/13007_CE[Ra1]_F(AK)_PF1(PAK)_PFA(AK)_PF2(PAG).pdfmetabolic adverse effectspsychosisrandomized controlled trial
collection DOAJ
language English
format Article
sources DOAJ
author TS DEEPAK
BN RAVEESH
BM PARASHIVAMURTHY
MS NARENDRA KUMAR
SUMANTH MALLIKARJUNA MAJGI
HN NAGESH
spellingShingle TS DEEPAK
BN RAVEESH
BM PARASHIVAMURTHY
MS NARENDRA KUMAR
SUMANTH MALLIKARJUNA MAJGI
HN NAGESH
Clinical Assessment of Weight Gain with Atypical Antipsychotics - Blonanserin vs Amisulpride
Journal of Clinical and Diagnostic Research
metabolic adverse effects
psychosis
randomized controlled trial
author_facet TS DEEPAK
BN RAVEESH
BM PARASHIVAMURTHY
MS NARENDRA KUMAR
SUMANTH MALLIKARJUNA MAJGI
HN NAGESH
author_sort TS DEEPAK
title Clinical Assessment of Weight Gain with Atypical Antipsychotics - Blonanserin vs Amisulpride
title_short Clinical Assessment of Weight Gain with Atypical Antipsychotics - Blonanserin vs Amisulpride
title_full Clinical Assessment of Weight Gain with Atypical Antipsychotics - Blonanserin vs Amisulpride
title_fullStr Clinical Assessment of Weight Gain with Atypical Antipsychotics - Blonanserin vs Amisulpride
title_full_unstemmed Clinical Assessment of Weight Gain with Atypical Antipsychotics - Blonanserin vs Amisulpride
title_sort clinical assessment of weight gain with atypical antipsychotics - blonanserin vs amisulpride
publisher JCDR Research and Publications Private Limited
series Journal of Clinical and Diagnostic Research
issn 2249-782X
0973-709X
publishDate 2015-06-01
description Background: Atypical antipsychotics appear to have the greatest potential to induce weight gain. Antipsychotic-induced weight gain is the one of main cause of non-compliance and discontinuation of treatment, often resulting in the relapse of psychosis. Objective: To compare the weight gain between amisulpride and blonanserin treatment, in persons with psychosis. Materials and Methods: Fifty six subjects with psychosis attending psychiatry department at KR Hospital, Mysore were randomized into two equal groups. After obtaining informed consent, subjects of group I received amisulpride tablets 200 mg BD, and group II received blonanserin tablets 4 mg BD, for eight weeks. Body weight, Body Mass Index (BMI) and Waist Hip Ratio (WHR) were measured at baseline, 4 weeks and 8 weeks. Results: The mean weight gain with amisulpride at 4 weeks was 2.73 kg (5.21%) and at 8 weeks was 4.34 kg (8.28%) from the baseline. The mean weight gain with blonanserin at 4 weeks was 1.77 kg (3.46%) and at 8 weeks was 3.46 kg (6.75%) from the baseline. The mean BMI increase at 8 weeks with amisulpride was 1.66 ± 0.56 and with blonanserin was 1.34 ± 0.77. The mean WHR increase at 8 weeks with amisulpride was 0.036 ± 0.026 and with blonanserin was 0.029 ± 0.020. There was statistically significant increase in weight, BMI and WHR associated with both blonanserin and amisulpride at 8 weeks. But there was no statistically significant difference in those parameters between blonanserin and amisulpride, at eight weeks. Conclusion: Even though there was no significant difference in the weight gain caused by blonanserin, in comparison with amisulpride, both these drugs individually caused significant weight gain at 8 weeks, which is in contrast with the earlier studies, which needs to be further evaluated.
topic metabolic adverse effects
psychosis
randomized controlled trial
url https://jcdr.net/articles/PDF/6066/13007_CE[Ra1]_F(AK)_PF1(PAK)_PFA(AK)_PF2(PAG).pdf
work_keys_str_mv AT tsdeepak clinicalassessmentofweightgainwithatypicalantipsychoticsblonanserinvsamisulpride
AT bnraveesh clinicalassessmentofweightgainwithatypicalantipsychoticsblonanserinvsamisulpride
AT bmparashivamurthy clinicalassessmentofweightgainwithatypicalantipsychoticsblonanserinvsamisulpride
AT msnarendrakumar clinicalassessmentofweightgainwithatypicalantipsychoticsblonanserinvsamisulpride
AT sumanthmallikarjunamajgi clinicalassessmentofweightgainwithatypicalantipsychoticsblonanserinvsamisulpride
AT hnnagesh clinicalassessmentofweightgainwithatypicalantipsychoticsblonanserinvsamisulpride
_version_ 1724435442398396416